Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Drug Delivery
    • Bioprocessing
    • Small Molecules
    • Cell and Gene
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Supply Chain
    • Regulation & Standards
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
    • eBooks
Subscribe
Subscribe
The Medicine Maker / Power List / 2017 / Champions of Change / Catherine Bollard

Catherine Bollard

President, International Society of Cellular Therapy, and Professor of Paediatrics, Children’s National Medical Centre Passion

  • Profile

Meet Catherine Bollard

Passion

“I always knew I wanted to pursue a career in Medicine, but I was also told at age 15 that I had a uniquely dramatic soprano singing voice. At 18 I was awarded a scholarship to pursue a career in singing in Australia and was accepted to Medical School. I was very conflicted, but decided to go to Medical School and make my decision after completing my medical degree. I eventually made the very difficult decision to set aside a career in music – which I have never regretted.”

Pivotal moment

“In the 1980s, my best friend in high school, Diana, developed Hodgkin’s lymphoma. Treatment comprised multiple cycles of chemo- and radiotherapy, but finally she went into remission. Later, she was diagnosed with myelodysplastic syndrome – a direct consequence of the Hodgkin’s therapy – and died soon afterwards. It was so cruel, and it became clear to me that we needed therapies that kill malignant cells and not bystander cells. As a result, I became interested in cellular immunotherapy.

“I ended up working on Hodgkin’s by chance when I moved to Houston. We’ve now developed a T-cell therapy that gives complete remissions in over 50 percent of some patient groups, and two-year progression-free survival rates of over 90 percent in other groups.

“If Diana had been diagnosed today, her outcome would have been completely different. Hence, I would say that this move to Houston and the serendipitous moment when I was able to develop a novel and ultimately, highly successful cell therapy for the same disease my friend had been diagnosed with was truly a pivotal moment in my career.”

False

Advertisement

Recommended

False

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.